Novel controlled-release polylactic-co-glycolic acid (PLGA) nanoparticles for sodium thiosulphate, a hydrogen sulphide donor, retains pro-angiogenic potential of hydrogen sulphide

References

• Lowicka E, Beltowski J. Hydrogen sulfide (H2S) - the third gas of interest for pharmacologists. Pharmacol Rep. 2007;59(1):4–24.
   Google Scholar
• Wang MJ, Cai WJ, Zhu YC. Hydrogen sulphide in cardiovascular system: a Cascade from interaction between sulphur atoms and signalling molecules. Life Sci. 2016;153:188–197.
   Google Scholar
• Polhemus DJ, Li Z, Pattillo CB, et al. A novel hydrogen sulfide prodrug, SG1002, promotes hydrogen sulfide and nitric oxide bioavailability in heart failure patients. Cardiovasc Ther. 2015;33(4):216–226.
   Google Scholar
• Pan LL, Qin M, Liu XH, et al. The role of hydrogen sulfide on cardiovascular homeostasis: an overview with update on immunomodulation. Front Pharmacol. 2017;8:686.
   Google Scholar
• Polhemus DJ, Calvert JW, Butler J, et al. The cardioprotective actions of hydrogen sulfide in acute myocardial infarction and heart failure. Scientifica (Cairo). 2014;2014:768607.
   Google Scholar
• Distrutti E, Sediari L, Mencarelli A, et al. Evidence that hydrogen sulfide exerts antinociceptive effects in the gastrointestinal tract by activating KATP channels. J Pharmacol Exp Ther. 2006;316(1):325–335.
   Google Scholar
• Paquette JM, Rufiange M, Iovu Niculita M, et al. Safety, tolerability and pharmacokinetics of trimebutine 3-thiocarbamoylbenzenesulfonate (GIC-1001) in a randomized phase I integrated design study: single and multiple ascending doses and effect of food in healthy volunteers. Clin Ther. 2014;36(11):1650–1664.
   Google Scholar
• Li L, Rose P, Moore PK. Hydrogen sulfide and cell signaling. Annu Rev Pharmacol Toxicol. 2011;51:169–187.
   Google Scholar
• Olson KR, DeLeon ER, Gao Y, et al. Thiosulfate: a readily accessible source of hydrogen sulfide in oxygen sensing. Am J Physiol Regul Integr Comp Physiol. 2013;305(6):R592–R603.
   Google Scholar
• de Koning M-S, Assa S, Maagdenberg CG, et al. Safety and tolerability of sodium thiosulfate in patients with an acute coronary syndrome undergoing coronary angiography: a Dose-Escalation safety pilot study (SAFE-ACS)). J Interv Cardiol. 2020;2020:6014915–6014915.
   Google Scholar
• Elrod JW, Calvert JW, Morrison J, et al. Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial function. Proc Natl Acad Sci USA. 2007;104(39):15560–15565.
   Google Scholar
• Li HZ, Sun WM, Li LN, et al. Exogenous H_2S contributes to recovery of ischemic post-conditioning-induced cardioprotection in the aging rat hearts and cardiomyocytes. 2016;8:2–11.
   Google Scholar
• Kondo K, Bhushan S, King AL, et al. H2S protects against pressure overload-induced heart failure via upregulation of endothelial nitric oxide synthase. Circulation. 2013;127(10):1116–1127.
   Google Scholar
• Pan LL, Liu XH, Shen YQ, et al. Inhibition of NADPH oxidase 4-related signaling by sodium hydrosulfide attenuates myocardial fibrotic response. Int J Cardiol. 2013;168(4):3770–3778.
   Google Scholar
• Nevozhay D, Kańska U, Budzyńska R, et al. [Current status of research on conjugates and related drug delivery systems in the treatment of cancer and other diseases]. Postepy Hig Med Dosw (Online). 2007;61:350–360.
   Google Scholar
• Cheng J, Teply BA, Sherifi I, et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials. 2007;28(5):869–876.
   Google Scholar
• Allen TM, Cullis PRJS. Drug delivery systems: entering the mainstream. Science. 2004;303(5665):1818–1822.
   Google Scholar
• Lavan DA, McGuire T, Langer RJNB. Small-scale systems for in vivo drug delivery. Nat Biotechnol. 2003;21(10):1184–1191.
   Google Scholar
• Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Delivery Rev. 2012;64:24–36.
   Google Scholar
• Avgoustakis K. Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery. Curr Drug Deliv. 2004;1(4):321–333.
   Google Scholar
• Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2010;75(1):1–18.
   Google Scholar
• Mu L, Feng SS. A novel controlled release formulation for the anticancer drug paclitaxel (taxol®): PLGA nanoparticles containing vitamin E TPGS. J Controlled Release. 2003;86(1):33–48.
   Google Scholar
• Jain RA. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials. 2000;21(23):2475–2490.
   Google Scholar
• Budhian A, Siegel SJ, Winey KI. Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content. Int J Pharm. 2007;336(2):367–375.
   Google Scholar
• Ali H, Opere C, Singh S. In vitro-controlled release delivery system for hydrogen sulfide donor. AAPS PharmSciTech. 2014;15(4):910–919.
   Google Scholar
• Lee J, Yang C, Ahn S, et al. Enhanced NO-induced angiogenesis via NO/H2S co-delivery from self-assembled nanoparticles [10.1039/D1BM00448D]. Biomater Sci. 2021;9(15):5150–5159.
   Google Scholar
• Sun X, Wang Y, Wen S, et al. Novel controlled and targeted releasing hydrogen sulfide system exerts combinational cerebral and myocardial protection after cardiac arrest. J Nanobiotechnol. 2021;19(1):40.
   Google Scholar
• Govender T, Stolnik S, Garnett MC, et al. PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J Control Release. 1999;57(2):171–185.
   Google Scholar
• Malik S, Lim J, Slack FJ, et al. Next generation miRNA inhibition using short anti-seed PNAs encapsulated in PLGA nanoparticles. J Control Release. 2020;327:406–419.
   Google Scholar
• Marwah M, Badhan RKS, Lowry D. Development of a novel polymer-based carrier for deformable liposomes for the controlled dermal delivery of naringenin. J Liposome Res. 2021;1–14.
   Google Scholar
• Schulz LT, Elder EJ, Jones KJ, et al. Stability of sodium nitroprusside and sodium thiosulfate 1:10 intravenous Admixture. Hosp Pharm. 2010;45(10):779–784.
   Google Scholar
• Gerő D, Torregrossa R, Perry A, et al. The novel mitochondria-targeted hydrogen sulfide (H2S) donors AP123 and AP39 protect against hyperglycemic injury in microvascular endothelial cells in vitro . Pharmacol Res. 2016;113(Pt A):186–198.
   Google Scholar
• Malik S, Slack FJ, Bahal R. Formulation of PLGA nanoparticles containing short cationic peptide nucleic acids. MethodsX. 2020;7:101115.
   Google Scholar
• Hillaireau H, Couvreur P. Nanocarriers’ entry into the cell: relevance to drug delivery. Cell Mol Life Sci. 2009;66(17):2873–2896.
   Google Scholar
• Fehrenbacher N, Jäättelä M. Lysosomes as targets for cancer therapy. Cancer Res. 2005;65(8):2993–2995.
   Google Scholar
• Peppas NA, Sahlin JJ. A simple equation for the description of solute release. III. Coupling of diffusion and relaxation. Int J Pharm. 1989;57(2):169–172.
   Google Scholar
• Liu YH, Lu M, Hu LF, et al. Hydrogen sulfide in the mammalian cardiovascular system. Antioxid Redox Signal. 2012;17(1):141–185.
   Google Scholar
• Qipshidze N, Metreveli N, Mishra PK, et al. Hydrogen sulfide mitigates cardiac remodeling during myocardial infarction via improvement of angiogenesis. Int J Biol Sci. 2012;8(4):430–441.
   Google Scholar
• Kasparek MS, Linden DR, Kreis ME, et al. Gasotransmitters in the gastrointestinal tract. Surgery. 2008;143(4):455–459.
   Google Scholar
• Kapoor DN, Bhatia A, Kaur R, et al. PLGA: a unique polymer for drug delivery. Ther Deliv. 2015;6(1):41–58.
   Google Scholar
• Makadia HK, Siegel SJ. Poly lactic-co-Glycolic acid (PLGA) as biodegradable controlled drug delivery Carrier. Polymers (Basel). 2011;3(3):1377–1397.
   Google Scholar
• Sadtler V, Rondon-Gonzalez M, Acrement A, et al. PEO-Covered nanoparticles by emulsion inversion point (EIP) method. Macromol Rapid Commun. 2010;31(11):998–1002.
   Google Scholar
• Feczkó T, Tóth J, Dósa G, et al. Influence of process conditions on the mean size of PLGA nanoparticles. Chem Eng Process. 2011;50(8):846–853.
   Google Scholar
• Mohammad AK, Reineke JJ. Quantitative detection of PLGA nanoparticle degradation in tissues following intravenous administration. Mol Pharm. 2013;10(6):2183–2189.
   Google Scholar
• Birnbaum DT, Brannon-Peppas L. Molecular weight distribution changes during degradation and release of PLGA nanoparticles containing epirubicin HCl. J Biomater Sci Polym Ed. 2003;14(1):87–102.
   Google Scholar
• Malinovskaya Y, Melnikov P, Baklaushev V, et al. Delivery of doxorubicin-loaded PLGA nanoparticles into U87 human glioblastoma cells. Int J Pharm. 2017;524(1–2):77–90.
   Google Scholar
• Ghitman J, Stan R, Ghebaur A, et al. Novel PEG-Modified hybrid PLGA-Vegetable oils nanostructured carriers for improving performances of indomethacin delivery. Polymers. 2018;10(6):579.
   Google Scholar
• Panyam J, Zhou W-Z, Prabha S, et al. Rapid endo-lysosomal escape of poly(DL-lactide-coglycolide) nanoparticles: implications for drug and gene delivery. FASEB J. 2002;16(10):1217–1226.
   Google Scholar
• Behzadi S, Serpooshan V, Sakhtianchi R, et al. Protein corona change the drug release profile of nanocarriers: the “overlooked” factor at the nanobio interface. Colloids Surf B Biointerfaces. 2014;123:143–149.
   Google Scholar
• Obst K, Yealland G, Balzus B, et al. Protein corona formation on colloidal polymeric nanoparticles and polymeric nanogels: impact on cellular uptake, toxicity, immunogenicity, and drug release properties. Biomacromolecules. 2017;18(6):1762–1771.
   Google Scholar